<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Plasma and platelet <z:e sem="disease" ids="C0042974" disease_type="Disease or Syndrome" abbrv="">von Willebrand</z:e> factor (vWF) measurements, multimeric pattern and subunit composition of plasma vWF were obtained in 29 consecutive patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloproliferative syndromes </plain></SENT>
<SENT sid="1" pm="."><plain>In the 8 patients with <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>), plasma vWF was significantly higher than in the 11 patients with <z:e sem="disease" ids="C0040028" disease_type="Disease or Syndrome" abbrv="">essential thrombocythemia</z:e> (ET) and in the 10 patients with <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>The RiCof/vWF:Ag ratio was low in <z:hpo ids='HP_0000001'>all</z:hpo> these groups of patients (mean 0.64 +/- 0.1, 0.66 +/- 0.2, and 0.61 +/- 0.2; <z:mpath ids='MPATH_458'>normal</z:mpath> 0.97 +/- 0.2) </plain></SENT>
<SENT sid="3" pm="."><plain><z:mp ids='MP_0001914'>Bleeding</z:mp> time was prolonged (&gt; 7.5 min) in 1/8 <z:mp ids='MP_0005481'>CML</z:mp> patients, 1/10 with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e>, and 3/11 with ET </plain></SENT>
<SENT sid="4" pm="."><plain>Plasma vWF multimers showed a minor loss of the largest multimers in 3/8 patients with <z:mp ids='MP_0005481'>CML</z:mp>, 4/10 with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e>, and a more severe reduction in 9/11 ET patients </plain></SENT>
<SENT sid="5" pm="."><plain>The latter pattern correlated with an abnormal proteolysis of vWF, expressed by a major increase of the 140-Kd fragment and decrease of the intact 225-Kd subunit in ET patients, whereas the 176-Kd fragment was significantly increased in <z:hpo ids='HP_0000001'>all</z:hpo> the subgroups of patients </plain></SENT>
<SENT sid="6" pm="."><plain>Platelet vWF was significantly higher in <z:mp ids='MP_0005481'>CML</z:mp> patients in comparison to ET and <z:mpath ids='MPATH_458'>normal</z:mpath> controls </plain></SENT>
<SENT sid="7" pm="."><plain>However, minor losses of the larger multimers were evident in <z:hpo ids='HP_0000001'>all</z:hpo> the subsets of patients </plain></SENT>
<SENT sid="8" pm="."><plain>In ET patients also the intermediate forms were lacking in platelets, accompanied by a significant decrease of platelet RiCof </plain></SENT>
<SENT sid="9" pm="."><plain>This abnormality was significantly correlated with the occurrence of <z:mp ids='MP_0001914'>bleeding</z:mp> symptoms in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e> and ET patients (P = 0.007; Fisher's exact test) </plain></SENT>
<SENT sid="10" pm="."><plain>In conclusion, plasma and platelet vWF abnormalities are common findings in myeloproliferative syndromes and are more severe in ET </plain></SENT>
<SENT sid="11" pm="."><plain>The more pronounced platelet vWF abnormalities in ET may reflect the more frequent <z:mp ids='MP_0001914'>bleeding</z:mp> symptoms observed in this disorder </plain></SENT>
</text></document>